Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
Eluminex announced today it acquired rights for a novel oral therapy to treat LCA or RP caused mutations of the RPE65 or LRAT gene.
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
New Treatments for Retinitis Pigmentosa
An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis
Gene therapy to halt rare form of sight loss
First Gene Therapy FDA-Approved for an Inherited Retinal Disease
FDA Approves Gene Therapy for Inherited Blindness Developed by the UPenn and CHOP